ABCL
ABCL
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
2
$1.64M
Insider Sales
0
$0
Total Volume
$1.64M
13 transactions
Net Activity
+$1.64M
Net buying
Sentiment Rating
Strong AccumulationCEO Conviction Index
No Recent Signal
Key Drivers
- •Strong buying bias: purchases represent 100% of total transaction value.
- •Minor cluster buying: 2 unique insiders purchased shares.
- •CFO buying activity detected. Statistical studies show CFO purchases have high predictive power due to their direct visibility into balance sheet details.
- •High accumulation: total purchase value exceeds $1M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Multiple Insiders
P - Purchase Insiders
$31582.19B total
Booth Andrew
CFO
$97K total
Quick Actions
ABCL has an insider buy conviction of 100%, compared to the Unknown sector buy average of 6%. ABCL ranks #475 in insider activity out of 570 tracked companies in its industry.
Over the last 90 days, corporate insiders at ABCL (ABCL) engaged in a total of 13 transactions reported via SEC Form 4 filings. Among these, 2 were open-market purchases and 0 were sales. The total volume of insider trading reached $1.64M.
The net insider activity for ABCL shows a net buying bias of $1.64M. This activity represents a 100% buy ratio, suggesting that insiders are currently strongly bullish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Multiple Insiders (P - Purchase Insiders), who traded 56.14M shares valued at $19292.70B on Mar 11, 2025.
ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know
AbCellera Biologics (ABCL) Stock Looks Reasonable Following Its 221% Run
ABCL - AbCellera Biologics Inc Stock Price and Quote
Hot-Flash Drug Trial Result Sends AbCellera Up as Much as 41%
Jefferies reiterates Buy on AbCellera stock, $21 target on VMS therapy
AbCellera Biologics (ABCL) Stock Sees Fair Value Lift After Clinical Data And Jazz Deal
FAQs About ABCL Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for ABCL.